Adaptin Bio Advances Novel Brain Cancer Treatment Candidate Towards Phase 1 Glioblastoma Clinical Trial
The Preston Robert Tisch Brain Tumor Center grants first IRB approval for APTN-101’s Phase I clinical trial, enabling patient recruitment to begin APTN-101, the Company’s Brain Bispecific T cell Engager (BRiTE), yields precise and potent anti-tumor …